
Sign up to save your podcasts
Or
In this week's episode we'll learn more about enhanced transplant characteristics; targeting the JAK-STAT pathway with ruxolitinib in patients with adult-onset Still’s disease and macrophage activation syndrome; and a pair of trials demonstrating lack of benefit for the anti-CD47 monoclonal antibody magrolimab in newly diagnosed acute myeloid leukemia.
Featured Articles
4.1
4848 ratings
In this week's episode we'll learn more about enhanced transplant characteristics; targeting the JAK-STAT pathway with ruxolitinib in patients with adult-onset Still’s disease and macrophage activation syndrome; and a pair of trials demonstrating lack of benefit for the anti-CD47 monoclonal antibody magrolimab in newly diagnosed acute myeloid leukemia.
Featured Articles
140 Listeners
324 Listeners
27 Listeners
507 Listeners
87 Listeners
1,120 Listeners
2 Listeners
196 Listeners
362 Listeners
2 Listeners
1 Listeners
29 Listeners
181 Listeners
48 Listeners
3 Listeners